Endothelium

World Precision Instruments Expands EVOM™ Auto with Both 24 and 96 Multiwell Plate Capability, Combining Transepithelial Electrical Resistance (TEER) Measurements with a High Throughput Format for Drug Discovery

Retrieved on: 
Monday, October 23, 2023
3D, Gastrointestinal tract, WPI, Skin, Research, Disinfectant, Drug development, Tissue, Traffic barrier, Lung, Endothelium, Orange County Convention Center, Medical imaging, Medical device

SARASOTA, Fla., Oct. 23, 2023 /PRNewswire/ -- World Precision Instruments (WPI) is excited to expand the capability of the EVOM™ Auto, now offering both 24 and 96 multiwell capacity in one single platform.

Key Points: 
  • SARASOTA, Fla., Oct. 23, 2023 /PRNewswire/ -- World Precision Instruments (WPI) is excited to expand the capability of the EVOM™ Auto, now offering both 24 and 96 multiwell capacity in one single platform.
  • The EVOM™ Auto enables rapid and reproducible measurements of Transepithelial Electrical Resistance (TEER), a well-established, non-invasive and widely accepted method of evaluating epithelial and endothelial cells and tissues.
  • WPI's EVOM™ Auto combines TEER technology, with high throughput screening capabilities, resulting in automated measurements of tissue and monolayer barrier integrity, cell permeability, and cell confluency.
  • "As we continue to enhance our TEER product offerings, we are excited to offer the additional capability to perform automated TEER measurements on the EVOM™ Auto in both 24 and 96 well plate formats.

eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys

Retrieved on: 
Wednesday, October 11, 2023
Xenotransplantation, Engineering, Biomarker, Hope, Inflammation, Genome, Endothelium, Risk, Data, Massachusetts General Hospital, Survival, Coagulation, Transplant, Hospital, Patient, Organ dysfunction, Pelvic floor dysfunction, Gene, Harvard Medical School, Transgene, NHP, Human, Filtration, Vaccine, Dentistry, Nature

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development.

Key Points: 
  • These results represent the largest and most comprehensive preclinical dataset published in the field to date.
  • Recipient survival in the preclinical setting has historically been measured in weeks or months.
  • The publication titled: “ Design and Testing of a Humanized Porcine Donor for Xenotransplantation ,” reported long-term survival of NHP recipients of the company’s genetically engineered porcine kidneys.
  • “At eGenesis, we are focused on transformational progress for the field – improving long-term survival for transplant recipients from months to years,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Retrieved on: 
Wednesday, July 26, 2023
Bevacizumab, IgG4-related ophthalmic disease, Clinical trial, Research, IVT, VEGF, Eye, Patient, European, Visual acuity, Death, KDR, Endothelium, Safety, Pharmaceutical industry, Vaccine, EU

This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).

Key Points: 
  • This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).
  • Part 2 was a single-arm, open-label, multicentre, phase II study and 20 patients (including 6 patients from part 1) were enrolled in this part.
  • As of now, the clinical trial applications of EB12-20145P (HLX04-O) had been approved in Singapore and other countries and regions.
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Retrieved on: 
Tuesday, July 18, 2023
GMP, DNA, CELU, Therapy, Macrophage, CTM, Instituto de Biologia Molecular e Celular, Research, Fibroblast, Cell, Human, GTP, EDT, Monocyte, Tehran International Conference on Disarmament and Non-Proliferation, Biomaterials Science, B cell, ECM, Cytokine, Tissue engineering, Phenotype, Conference, Endothelium, Wound healing, Pharmaceutical industry, Silk

Benchtop data to be presented demonstrate that:

Key Points: 
  • Benchtop data to be presented demonstrate that:
    DDHAM modulates macrophage behavior, promoting polarization into M2 phenotype, and serves as a scaffold for endogenous cell attachment and proliferation in wound healing.
  • DDHAM-3L supports human corneal epithelial cell activity and attenuates an inflammatory response over time.
  • We believe our unique proprietary process provides superior biocompatibility, and better supports differentiated cell functions, as compared with other human placental-derived biomaterials which may contain cellular residuals,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder.
  • We leverage a diversified portfolio of therapeutic technologies all derived from a single source material — the post-partum placenta.

CoImmune Announces Publication of Preclinical Data Demonstrating Efficacy and Specificity of CAR-CIK Cells in Acute Myeloid Leukemia

Retrieved on: 
Wednesday, July 5, 2023
HSPC, University, Pediatrics, Toxicity, Acute myeloid leukemia, CAR, AML, Science, Cytokine release syndrome, Patient, CD33, CD123, American Society of Hematology, Risk, Growth, Toxic shock syndrome toxin-1, Leukemia, Society, Endothelium, University of Milano-Bicocca, Vaccine

DURHAM, N.C., July 5, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the publication of preclinical data demonstrating that a strategy based on the company's proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML). The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.

Key Points: 
  • The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.
  • The dual strategy demonstrated powerful antitumor efficacy against AML targets without any relevant toxicity on hematopoietic stem and progenitor cells (HSPCs) and endothelial cells.
  • Specifically, the researchers found:
    CD123 and/or CD33 knockout impairs leukemia growth by modulating multiple cancer pathways in a model of NPM1-mutated AML.
  • Low affinity CAR-CIK cells preserve antileukemic efficacy in vitro and improve antitumor control in vivo.

Hesperos Scientists Publish a New Study in Scientific Reports Titled: "Development of a Human Malaria-on-a-Chip Disease Model for Drug Efficacy and Off-Target Toxicity Evaluation"

Retrieved on: 
Wednesday, July 5, 2023
Other Health, Research, General Health, Pharmaceutical, Hardware, Technology, Science, Nanotechnology, Biotechnology, Other Technology, Other Science, Health, Red, Drug development, Failure, Medicines for Malaria Venture, Parasitism, Fever, Skin, Endothelium, Woman, Animal, W2, Spleen, MMV, Scientific Reports, Drug discovery, Plasmodium falciparum, Nausea, Liver, Chloroquine, Parasitemia, Behavior, World Health Organization, Disease, Vaccine, Medical device, Nature, Malaria, Plasmodium

In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.

Key Points: 
  • In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.
  • Through their efforts they developed a human-based model to study the disease pathology and therapeutic effects in a pre-clinical platform.
  • This microfluidic platform connects human liver, spleen, and endothelium with recirculating human erythrocytes in a controlled, self-contained platform.
  • This new approach to the evaluation of Plasmodium falciparum and anti-malarial therapeutics is executed in a realistic human model.

The lesser-known risk factors for heart disease

Retrieved on: 
Thursday, June 15, 2023
People, Heart, Longest NCAA Division I football winning streaks, Gout, Plaque, Smoking, Diet, Health, Canakinumab, Stroke, Cholesterol, Infection, Atherosclerosis, Cardiovascular disease, Clinical trial, Splenic infarction, Quality of life, Endothelium, Methotrexate, Grain boundary strengthening, Brain, Artery, Risk, Fruit, Cell, Inflammation, Vegetable, Obesity, Facial muscles, Psoriasis, Inflammatory bowel disease, Colchicine, Membrane protein, Rupture, Patient, Time, Blood, LDL, Immune system, Overweight, Fatty streak, Body mass index, Moyamoya disease, Coronary artery disease, Research, Exercise, The Cantos, Rheumatoid arthritis, Pharmaceutical industry, Medical imaging, Dietary supplement, Dentistry, ASCVD

Most people know that the risk factors for heart disease are high blood pressure, smoking, raised cholesterol and being overweight.

Key Points: 
  • Most people know that the risk factors for heart disease are high blood pressure, smoking, raised cholesterol and being overweight.
  • However, many people who have a heart attack do not have any of these traditional risk factors.
  • Research has suggested that conditions such as gout, psoriasis, inflammatory bowel disease and rheumatoid arthritis are also risk factors for heart disease.
  • Long-term inflammation of the arteries supplying the heart and brain can eventually lead to heart attacks and strokes.
  • Because this chronic inflammatory process happens silently, many patients without traditional risk factors for heart disease will not be aware that they are at an increased risk of heart disease.

Measuring inflammation

    • However, the study was considered groundbreaking in that it supported the hypothesis that inflammation plays an important role in ASCVD, and that targeting inflammation may be useful to reduce the risk of repeat cardiovascular events.
    • Also, this may enable us to focus on treating inflammation in order to reduce cardiovascular risk.
    • Already, several studies are looking at using cheaper anti-inflammatory drugs, such as colchicine and methotrexate, to reduce inflammation and prevent the progression of cardiovascular disease.

Lifestyle changes to reduce inflammation

    • Fortunately, it is possible to reduce inflammation in our bodies without resorting to drugs.
    • Losing weight around your midsection will help to reduce this inflammation.
    • By making anti-inflammatory choices and leading a healthy lifestyle we can all reduce our chances of developing heart disease and improve our quality of life.

Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round

Retrieved on: 
Wednesday, June 7, 2023
Clinical Trials, Professional Services, Stem Cells, Biotechnology, Health, University, Optical, Other Professional Services, Education, Freedom, BoB and Partners Co. Ltd., Fujita Health University, Cornea, Shanghai Venture Capital Co., Inc., Fosun Pharma, Seed, Head, Cataract, Visual impairment, Hope, Research, Keio University, Paratriathlon, Cell, AIS, Human, Regenerative medicine, QOL, Patient, Opacity, JIC, R, IPS, Endothelium, Disease, Pharmaceutical industry, Security (finance), Fine chemical, Vaccine, Greater China

Cellusion Inc. (Head Office: Tokyo; CEO: Shin Hatou; hereinafter referred to as “Cellusion”) announced that it has raised 2.83 billion yen (21 million USD) in Series C Round financing.

Key Points: 
  • Cellusion Inc. (Head Office: Tokyo; CEO: Shin Hatou; hereinafter referred to as “Cellusion”) announced that it has raised 2.83 billion yen (21 million USD) in Series C Round financing.
  • To date, Cellusion has reinforced its organizational structure for R&D, etc.
  • and promoted overseas operations in the Greater China by executing a license agreement with Celregen, a subsidiary of Fosun Pharma, in September 2022.
  • The University of Tokyo Edge Capital Partners Co., Ltd., Principal, Hiroaki Kobayashi
    Continuing from our Series B investment, we have also steadfastly made an additional investment in this Round.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting

Retrieved on: 
Monday, May 8, 2023
Health, Surgery, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Fuchs, Abstract, Cornea, Descemet's membrane, Mayo Clinic, Refractive surgery, Epithelium, Fibroblast growth factor, CCT, Quality of life, Endothelium, Hope, Research, ASCRS, DSO, Fuchs' dystrophy, American Society of Cataract and Refractive Surgery, Risk, FGF1, Annual general meeting, Disease, Cataract, GLARE, Therapy, Society, Safety, Fibroblast growth factor receptor 2, Pharmaceutical industry, Medical imaging, Patient

A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).

Key Points: 
  • A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).
  • The data were presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.
  • The study results showed TTHX1114 improved best-corrected visual acuity (BCVA) and central corneal thickness (CCT) after DSO in the 49 subjects/64 eyes.
  • Faster recovery was associated with smaller descemetorhexis (surgical removal of Descemet membrane), while comorbid diabetes appeared to delay recovery.